France Biotech, France Deeptech and Future4Care join forces to accelerate the development of TechBio in France.

At the AI Action Summit Business Day held at Station F on Tuesday February 11, France Biotech, France Deeptech and Future4Care announced the signing of a strategic partnership agreement.

Launched at the initiative of David Del Bourgo, CEO and co-founder of WhiteLab Genomics, this action aims to structure and develop the TechBio sector in France through the creation of a dedicated working committee. This new commission will be tasked with fostering collaboration between TechBio players, improving access to healthcare data - essential for these innovative companies - and structuring the French TechBio sector.

At the signing ceremony, Frédéric Girard, President of France Biotech, Michel de Lempdes, President of France Deeptech and Agnès De Leersnyder, CEO of Future4Care, discussed the objectives of this strategic initiative, which follows on from the work of the “AI & Biodiscovery” expertise group launched in 2024 by France Biotech, and more broadly the challenges of this emerging sector.

 “AI offers a major opportunity to accelerate drug discovery and development. By adopting these new technologies from the hard sciences, biotechs and pharmaceutical companies can accelerate and secure their R&D for the benefit of patients, while reducing the cost, risk and timeframe of clinical developments,” said Frédéric Girard, President of France Biotech, underlining the importance of this collaboration in strengthening the French ecosystem and, ultimately, France's sovereignty.

 For Michel de Lempdes, President of France Deeptech, “this partnership is an essential step forward in structuring the development of TechBio in France. By bringing together the strengths of AI and biotechnology, we are creating a framework conducive to innovation, for the benefit of patients and the competitiveness of our sector.”

Agnès De Leersnyder, CEO of Future4Care, comments: “This partnership is a key step in structuring this fast-growing market. Future4Care is delighted to support TechBio companies through its gas pedal, creating the right conditions for their integration into the pharmaceutical industry”.

For David Del Bourgo, CEO and co-founder of WhiteLab Genomics, and co-coordinator of this new TechBio commission: “This commission was created to structure an economic ecosystem in a sector that is still little-known but extremely promising. We are fully committed to accelerating the development of TechBio companies, which are distinguished by their dynamism in France and actively contribute to the influence of innovation in our country”.

TechBio: a booming industry

TechBio makes it possible to better predict drug-target interactions, identify biomarkers and develop personalized treatments that are better adapted to patients. This sector, which combines advances in biotechnology and artificial intelligence, is booming in France. France Biotech's “AI & Biodiscovery” expertise group, in partnership with companies such as Adlin Science, Orakl Oncology and WhiteLab Genomics, recently mapped the French players in this field.

This study has enabled us to gain a better understanding of the economic and technological challenges facing these companies, as well as their financing and market access requirements. Today, the sector comprises some twenty French companies, most of which are focused on the development of proprietary assets. These innovations require privileged access to healthcare data, a strategic challenge for strengthening their international competitiveness.

Working together to shape the future of healthcare innovation

Thanks to this joint working committee, France Biotech and France Deeptech, with the support of Future4Care, intend to promote synergies between startups, researchers, manufacturers and investors, to accelerate innovation for the benefit of patients and European healthcare sovereignty.

About France Biotech

France Biotech, founded in 1997, is an independent association that brings together entrepreneurs in healthcare innovation and their expert partners. As the driving force behind the 2,600-strong healthcare innovation ecosystem, and a privileged interlocutor for public authorities in France and Europe, France Biotech contributes to meeting the challenges facing the HealthTech sector (company financing, innovation taxation, regulatory issues and market access, etc.) and to proposing concrete solutions, in terms of competitiveness and attractiveness, through its commissions and working groups. France Biotech is housed at the PariSanté Campus. http://www.france-biotech.fr/ Press contact: France Biotech // Florence Portejoie, FP2COM, fportejoie@fp2com.fr, 06 07 76 82 83

About France Deeptech

France Deeptech is an association created in 2023, open to all deeptech players in a logic of ecosystem, partnership and healthy creative emulation. Its objective is to bring together and federate the various players in the French and European deeptech sector, in particular entrepreneurs, deeptech investors and research laboratories, in order to encourage the emergence and/or rapid growth of ambitious and daring entrepreneurial projects capable of making a decisive contribution to solving major contemporary challenges, and maintaining French and European competitiveness and technological independence, which are key to sovereignty and freedom.

About Future4care

Future4care is a European ecosystem of multidisciplinary players dedicated to digital health. A joint venture founded in 2021 by the alliance of Capgemini, Generali, Orange and Sanofi, Future4care brings together E-health players (major groups, experts, healthcare professionals, startups, etc.) to create synergies and opportunities that will accelerate progress in digital healthcare. Since its launch, Future4care has brought together seven industrial and institutional partners (Alira Health, Be-ys, Biocodex, Elior, Havas Life, TNP, UCB and FEHAP) and qualified personalities from the scientific and academic worlds within a Scientific and Ethical Council.

About WhiteLab Genomics

WhiteLab Genomics, a pioneer in the accelerated development of genomic medicine, stands at the convergence of computer science and biology. Founded in 2019 and backed by YCombinator, it is establishing itself as a key player in genomics innovation. Its platform provides in silico simulations to discover and design optimized therapies. WhiteLab aims to accelerate the drug development process, reduce costs and bring genomic medicines to market faster. The company collaborates with leading pharmaceutical companies such as Sanofi, academic institutions and innovative biotech companies. WhiteLab Genomics is part of the prestigious French Tech 2030 program supported by the French government, and recently joined the Bayer Co.Lab in Cambridge, Massachusetts.